WO2000021954A1 - Neue heterocyclyl-methyl-substituierte pyrazole - Google Patents
Neue heterocyclyl-methyl-substituierte pyrazole Download PDFInfo
- Publication number
- WO2000021954A1 WO2000021954A1 PCT/EP1999/007202 EP9907202W WO0021954A1 WO 2000021954 A1 WO2000021954 A1 WO 2000021954A1 EP 9907202 W EP9907202 W EP 9907202W WO 0021954 A1 WO0021954 A1 WO 0021954A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbon atoms
- chain
- straight
- substituted
- branched
- Prior art date
Links
- 150000003217 pyrazoles Chemical class 0.000 title claims description 5
- 238000000034 method Methods 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 11
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 554
- 125000000217 alkyl group Chemical group 0.000 claims description 211
- 125000003545 alkoxy group Chemical group 0.000 claims description 152
- 125000002252 acyl group Chemical group 0.000 claims description 115
- -1 hydroxy, Amino Chemical group 0.000 claims description 105
- 150000003254 radicals Chemical class 0.000 claims description 100
- 239000001257 hydrogen Substances 0.000 claims description 89
- 229910052739 hydrogen Inorganic materials 0.000 claims description 89
- 239000000460 chlorine Substances 0.000 claims description 80
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 75
- 229910052801 chlorine Inorganic materials 0.000 claims description 75
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 67
- 229910052717 sulfur Inorganic materials 0.000 claims description 65
- 229910052760 oxygen Inorganic materials 0.000 claims description 64
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 64
- 239000011737 fluorine Substances 0.000 claims description 62
- 229910052731 fluorine Inorganic materials 0.000 claims description 62
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 58
- 125000000623 heterocyclic group Chemical group 0.000 claims description 56
- 150000001875 compounds Chemical class 0.000 claims description 52
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 50
- 229910052736 halogen Inorganic materials 0.000 claims description 49
- 150000002367 halogens Chemical class 0.000 claims description 49
- 125000005842 heteroatom Chemical group 0.000 claims description 45
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 44
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 44
- 229910052794 bromium Inorganic materials 0.000 claims description 44
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 41
- 125000003118 aryl group Chemical group 0.000 claims description 38
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 34
- 125000001153 fluoro group Chemical group F* 0.000 claims description 34
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 31
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 29
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 28
- 150000002431 hydrogen Chemical class 0.000 claims description 26
- 125000001072 heteroaryl group Chemical group 0.000 claims description 25
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 23
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 22
- 125000004414 alkyl thio group Chemical group 0.000 claims description 22
- 239000001301 oxygen Substances 0.000 claims description 22
- 125000004434 sulfur atom Chemical group 0.000 claims description 22
- 229920006395 saturated elastomer Polymers 0.000 claims description 21
- 125000003342 alkenyl group Chemical group 0.000 claims description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims description 19
- 125000000304 alkynyl group Chemical group 0.000 claims description 18
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 125000004442 acylamino group Chemical group 0.000 claims description 16
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical group CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 claims description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 10
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 230000009467 reduction Effects 0.000 claims description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 150000001204 N-oxides Chemical class 0.000 claims description 8
- 150000001409 amidines Chemical class 0.000 claims description 8
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 8
- 239000012442 inert solvent Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 150000005840 aryl radicals Chemical class 0.000 claims description 7
- 150000002081 enamines Chemical class 0.000 claims description 7
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 7
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 6
- 125000004423 acyloxy group Chemical group 0.000 claims description 6
- 125000005042 acyloxymethyl group Chemical group 0.000 claims description 6
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 6
- AJXWEJAGUZJGRI-UHFFFAOYSA-N fluorine azide Chemical compound FN=[N+]=[N-] AJXWEJAGUZJGRI-UHFFFAOYSA-N 0.000 claims description 6
- 125000005368 heteroarylthio group Chemical group 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 5
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 125000002541 furyl group Chemical group 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 239000011630 iodine Substances 0.000 claims description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
- 125000005110 aryl thio group Chemical group 0.000 claims description 4
- 206010008118 cerebral infarction Diseases 0.000 claims description 4
- CPPKAGUPTKIMNP-UHFFFAOYSA-N cyanogen fluoride Chemical group FC#N CPPKAGUPTKIMNP-UHFFFAOYSA-N 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000002757 morpholinyl group Chemical group 0.000 claims description 3
- 239000002840 nitric oxide donor Substances 0.000 claims description 3
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims description 3
- 230000003647 oxidation Effects 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 3
- 125000004193 piperazinyl group Chemical group 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 2
- JYLNFIMUITVMBA-UHFFFAOYSA-N 1-fluoro-2-methylhydrazine Chemical compound CNNF JYLNFIMUITVMBA-UHFFFAOYSA-N 0.000 claims description 2
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims description 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 2
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- OEORWRSNGNVLBV-UHFFFAOYSA-N [amino(methoxy)-lambda3-chloranyl]formonitrile Chemical compound NCl(OC)C#N OEORWRSNGNVLBV-UHFFFAOYSA-N 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 claims description 2
- 238000006555 catalytic reaction Methods 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- VBYIVPZYCNKFFD-UHFFFAOYSA-N n-fluorohydroxylamine Chemical compound ONF VBYIVPZYCNKFFD-UHFFFAOYSA-N 0.000 claims description 2
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 238000007796 conventional method Methods 0.000 claims 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 239000000203 mixture Substances 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 8
- 229930195733 hydrocarbon Natural products 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 239000004215 Carbon black (E152) Substances 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 0 *c1n[n](Cc(cccc2)c2F)c2ccccc12 Chemical compound *c1n[n](Cc(cccc2)c2F)c2ccccc12 0.000 description 4
- QPFMBZIOSGYJDE-UHFFFAOYSA-N 1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)C(Cl)Cl QPFMBZIOSGYJDE-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940052308 general anesthetics halogenated hydrocarbons Drugs 0.000 description 3
- 150000008282 halocarbons Chemical class 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 229910052987 metal hydride Inorganic materials 0.000 description 3
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 2
- FFWQLZFIMNTUCZ-UHFFFAOYSA-N 1-(bromomethyl)-2-fluorobenzene Chemical compound FC1=CC=CC=C1CBr FFWQLZFIMNTUCZ-UHFFFAOYSA-N 0.000 description 2
- REHRQXVEAXFIML-UHFFFAOYSA-N 1h-indazole-3-carbonitrile Chemical class C1=CC=C2C(C#N)=NNC2=C1 REHRQXVEAXFIML-UHFFFAOYSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 2
- SEQWNBBMRHGRPX-UHFFFAOYSA-N 4-amino-2-chloropyrimidine-5-carboxamide Chemical compound NC(=O)C1=CN=C(Cl)N=C1N SEQWNBBMRHGRPX-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- RXYPXQSKLGGKOL-UHFFFAOYSA-N CN1CCN(C)CC1 Chemical compound CN1CCN(C)CC1 RXYPXQSKLGGKOL-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- ZGRQPKYPJYNOKX-XUXIUFHCSA-N Cys-Cys-His-His Chemical compound C([C@H](NC(=O)[C@H](CS)NC(=O)[C@H](CS)N)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 ZGRQPKYPJYNOKX-XUXIUFHCSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010078321 Guanylate Cyclase Proteins 0.000 description 2
- 102000014469 Guanylate cyclase Human genes 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 2
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 2
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 2
- 229910001863 barium hydroxide Inorganic materials 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000009530 blood pressure measurement Methods 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 229950005499 carbon tetrachloride Drugs 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 229960001701 chloroform Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 2
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 239000000066 endothelium dependent relaxing factor Substances 0.000 description 2
- 150000002085 enols Chemical class 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000004681 metal hydrides Chemical class 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 2
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 229960001802 phenylephrine Drugs 0.000 description 2
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 229940083618 sodium nitroprusside Drugs 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 150000003460 sulfonic acids Chemical class 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- FOTRKCAZUSJCQD-UHFFFAOYSA-N (methylsulfonyl)acetonitrile Chemical compound CS(=O)(=O)CC#N FOTRKCAZUSJCQD-UHFFFAOYSA-N 0.000 description 1
- UKDOTCFNLHHKOF-FGRDZWBJSA-N (z)-1-chloroprop-1-ene;(z)-1,2-dichloroethene Chemical group C\C=C/Cl.Cl\C=C/Cl UKDOTCFNLHHKOF-FGRDZWBJSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- OMYYVJHIZOKONH-UHFFFAOYSA-N 1-[(2-fluorophenyl)methyl]-1h-indazol-1-ium-3-carboximidamide;chloride Chemical compound Cl.C12=CC=CC=C2C(C(=N)N)=NN1CC1=CC=CC=C1F OMYYVJHIZOKONH-UHFFFAOYSA-N 0.000 description 1
- ITILKBNLQYKFMP-UHFFFAOYSA-N 1-[(2-fluorophenyl)methyl]-3-iodoindazole Chemical compound FC1=CC=CC=C1CN1C2=CC=CC=C2C(I)=N1 ITILKBNLQYKFMP-UHFFFAOYSA-N 0.000 description 1
- AGYZSSWNSPUHRM-UHFFFAOYSA-N 1-[(2-fluorophenyl)methyl]indazole-3-carbonitrile Chemical compound FC1=CC=CC=C1CN1C2=CC=CC=C2C(C#N)=N1 AGYZSSWNSPUHRM-UHFFFAOYSA-N 0.000 description 1
- DREPONDJUKIQLX-UHFFFAOYSA-N 1-[ethenyl(ethoxy)phosphoryl]oxyethane Chemical compound CCOP(=O)(C=C)OCC DREPONDJUKIQLX-UHFFFAOYSA-N 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- DZTIFMWYYHCREC-UHFFFAOYSA-N 2,4-dichloropyrimidine-5-carbonyl chloride Chemical compound ClC(=O)C1=CN=C(Cl)N=C1Cl DZTIFMWYYHCREC-UHFFFAOYSA-N 0.000 description 1
- YZLGKWXKBAINDU-UHFFFAOYSA-N 2-[1-[(2-fluorophenyl)methyl]indazol-3-yl]-5-methylsulfonylpyrimidin-4-amine Chemical compound N1=C(N)C(S(=O)(=O)C)=CN=C1C(C1=CC=CC=C11)=NN1CC1=CC=CC=C1F YZLGKWXKBAINDU-UHFFFAOYSA-N 0.000 description 1
- FDINIADGJDOBKZ-UHFFFAOYSA-N 2-[1-[(2-fluorophenyl)methyl]indazol-3-yl]-5-pyridin-2-ylpyrimidin-4-amine Chemical compound NC1=NC(C=2C3=CC=CC=C3N(CC=3C(=CC=CC=3)F)N=2)=NC=C1C1=CC=CC=N1 FDINIADGJDOBKZ-UHFFFAOYSA-N 0.000 description 1
- CTVSKGBGQYWACQ-UHFFFAOYSA-N 2-[1-[(2-fluorophenyl)methyl]indazol-3-yl]-5-pyridin-2-ylsulfonylpyrimidin-4-amine Chemical compound NC1=NC(C=2C3=CC=CC=C3N(CC=3C(=CC=CC=3)F)N=2)=NC=C1S(=O)(=O)C1=CC=CC=N1 CTVSKGBGQYWACQ-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- KWMBADTWRIGGGG-UHFFFAOYSA-N 2-diethoxyphosphorylacetonitrile Chemical compound CCOP(=O)(CC#N)OCC KWMBADTWRIGGGG-UHFFFAOYSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- YGCYQSVPXXQVCC-UHFFFAOYSA-N 3-(dimethylamino)-2-methylsulfonylprop-2-enenitrile Chemical compound CN(C)C=C(C#N)S(C)(=O)=O YGCYQSVPXXQVCC-UHFFFAOYSA-N 0.000 description 1
- HQVNVYFIPYMSHH-UHFFFAOYSA-N 3-(dimethylamino)-2-pyridin-2-ylprop-2-enenitrile Chemical compound CN(C)C=C(C#N)C1=CC=CC=N1 HQVNVYFIPYMSHH-UHFFFAOYSA-N 0.000 description 1
- RVBXUBSQJKKTJF-UHFFFAOYSA-N 3-(dimethylamino)-2-pyridin-2-ylsulfonylprop-2-enenitrile Chemical compound CN(C)C=C(C#N)S(=O)(=O)C1=CC=CC=N1 RVBXUBSQJKKTJF-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UDKYMMQGPNFWDA-UHFFFAOYSA-N 3-iodo-2h-indazole Chemical compound C1=CC=CC2=C(I)NN=C21 UDKYMMQGPNFWDA-UHFFFAOYSA-N 0.000 description 1
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BMTAFVWTTFSTOG-UHFFFAOYSA-N Butylate Chemical compound CCSC(=O)N(CC(C)C)CC(C)C BMTAFVWTTFSTOG-UHFFFAOYSA-N 0.000 description 1
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N CN1CCNCC1 Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N CN1CCOCC1 Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- LNJMHEJAYSYZKK-UHFFFAOYSA-N Cc1ncccn1 Chemical compound Cc1ncccn1 LNJMHEJAYSYZKK-UHFFFAOYSA-N 0.000 description 1
- LVILGAOSPDLNRM-UHFFFAOYSA-N Cc1ncncc1 Chemical compound Cc1ncncc1 LVILGAOSPDLNRM-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- KEHRTIGDVOZAAA-UHFFFAOYSA-N N1=C(N)C(P(=O)(OC(C)C)OC(C)C)=CN=C1C(C1=CC=CC=C11)=NN1CC1=CC=CC=C1F Chemical compound N1=C(N)C(P(=O)(OC(C)C)OC(C)C)=CN=C1C(C1=CC=CC=C11)=NN1CC1=CC=CC=C1F KEHRTIGDVOZAAA-UHFFFAOYSA-N 0.000 description 1
- YJJQEOAMMHRJAA-UHFFFAOYSA-N N1=C(N)C(P(=O)(OCC)OCC)=CN=C1C(C1=CC=CC=C11)=NN1CC1=CC=CC=C1F Chemical compound N1=C(N)C(P(=O)(OCC)OCC)=CN=C1C(C1=CC=CC=C11)=NN1CC1=CC=CC=C1F YJJQEOAMMHRJAA-UHFFFAOYSA-N 0.000 description 1
- NLEQLYPPDJOBQN-UHFFFAOYSA-N NC(c1cnc(-c2n[n](Cc3ccccc3F)c3ccccc23)nc1N)=O Chemical compound NC(c1cnc(-c2n[n](Cc3ccccc3F)c3ccccc23)nc1N)=O NLEQLYPPDJOBQN-UHFFFAOYSA-N 0.000 description 1
- VFZXVONSQCNCAT-UHFFFAOYSA-N NONOate(1-) Chemical compound CCN(CC)N([O-])N=O VFZXVONSQCNCAT-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 108700043492 SprD Proteins 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 238000005874 Vilsmeier-Haack formylation reaction Methods 0.000 description 1
- FNEMEKNMVUACNG-UHFFFAOYSA-N [1-[(2-fluorophenyl)methyl]indazol-3-yl]-trimethylstannane Chemical compound C12=CC=CC=C2C([Sn](C)(C)C)=NN1CC1=CC=CC=C1F FNEMEKNMVUACNG-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 150000007960 acetonitrile Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000007854 aminals Chemical class 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical class B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006251 butylcarbonyl group Chemical group 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 150000002084 enol ethers Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000006328 iso-butylcarbonyl group Chemical group [H]C([H])([H])C([H])(C(*)=O)C([H])([H])[H] 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 229960003827 isosorbide mononitrate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- HZRMTWQRDMYLNW-UHFFFAOYSA-N lithium metaborate Chemical compound [Li+].[O-]B=O HZRMTWQRDMYLNW-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 1
- 229960004027 molsidomine Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- HXRAMSFGUAOAJR-UHFFFAOYSA-N n,n,n',n'-tetramethyl-1-[(2-methylpropan-2-yl)oxy]methanediamine Chemical compound CN(C)C(N(C)C)OC(C)(C)C HXRAMSFGUAOAJR-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 150000002941 palladium compounds Chemical class 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000004031 phenylhydrazines Chemical class 0.000 description 1
- 150000003008 phosphonic acid esters Chemical class 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
- JVUYWILPYBCNNG-UHFFFAOYSA-N potassium;oxido(oxo)borane Chemical compound [K+].[O-]B=O JVUYWILPYBCNNG-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004673 propylcarbonyl group Chemical group 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 229950003776 protoporphyrin Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- ZZYXNRREDYWPLN-UHFFFAOYSA-N pyridine-2,3-diamine Chemical compound NC1=CC=CN=C1N ZZYXNRREDYWPLN-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- NVIFVTYDZMXWGX-UHFFFAOYSA-N sodium metaborate Chemical compound [Na+].[O-]B=O NVIFVTYDZMXWGX-UHFFFAOYSA-N 0.000 description 1
- SUBJHSREKVAVAR-UHFFFAOYSA-N sodium;methanol;methanolate Chemical compound [Na+].OC.[O-]C SUBJHSREKVAVAR-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229960003279 thiopental Drugs 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- PZRXQXJGIQEYOG-UHFFFAOYSA-N zinc;oxido(oxo)borane Chemical compound [Zn+2].[O-]B=O.[O-]B=O PZRXQXJGIQEYOG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
Definitions
- the present invention relates to new heterocyclyl-methyl-substituted pyrazole derivatives, ner processes for their preparation and their use as medicaments, in particular as medicaments for the treatment of cardiovascular diseases.
- the present invention relates to new heterocyclyl-methyl-substituted pyrazoles of the general formula (I)
- R 1 represents a 6-membered aromatic heterocycle with up to 3 nitrogen atoms, which may be up to 2 times identical or different by hydrogen, formyl, carboxyl, hydroxy, mercapto, straight-chain or branched acyl, alkoxy, alkylthio or alkoxycarbonyl, each with up to to to
- R 4 and R 5 are identical or different and are hydrogen or straight-chain or branched acyl having up to 6 carbon atoms or straight-chain or branched alkyl having up to 6 carbon atoms, which may be by cycloalkyl having 3 to 6 carbon atoms, hydroxyl, amino or by straight-chain or branched alkoxy, acyl or alkoxycarbonyl, each having up to 5 carbon atoms,
- R 4 and R 5 together with the nitrogen atom form a 3- to 7-membered saturated or partially unsaturated heterocycle which may optionally additionally contain an oxygen or sulfur atom or a radical of the formula -NR 6 ,
- R 6 represents hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms
- R 7 denotes straight-chain or branched acyl having up to 5 carbon atoms or a group of the formula -SiR 8 R 9 R 10 , wo ⁇ n
- R 8 , R 9 and R ! 0 are the same or different and are aryl with 6 to 10 carbon atoms or alkyl with up to 6 carbon atoms,
- b and b ' are the same or different and represent a number 0, 1, 2 or 3,
- a represents a number 1, 2 or 3
- R 11 denotes hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms
- c represents a number 1 or 2
- R 12 and R 13 are the same or different and is hydrogen or straight-chain or branched alkyl having up to 10 carbon atoms, which is optionally by cycloalkyl
- R 12 and R 13 together with the nitrogen atom form a 5- to 7-membered saturated heterocycle which can optionally contain a further oxygen atom or a radical -NR 14 ,
- R 14 is hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms or a radical of the formula
- alkenyl or alkynyl have a double or triple bond at the point of attachment to the heterocycle R 1 ,
- R a and R b are identical or different and are hydrogen or straight-chain or branched acyl having up to 10 carbon atoms, cyclic acyl having 3 to 8 carbon atoms, straight-chain or branched alkyl having up to 10 carbon atoms or cycloalkyl having 3 to 14 carbon atoms, where appropriate by
- R a and R together with the nitrogen atom form a 3- to 7-membered saturated or partially unsaturated heterocycle, which may be by
- Hydroxy is substituted and which optionally additionally contains an oxygen or sulfur atom or a radical of the formula -NR C ,
- R ° is hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms
- R d denotes straight-chain or branched acyl having up to 5 carbon atoms or a group of the formula -SiR e R f R 8 ,
- R e , R f and R 8 are the same or different and are aryl with 6 to 10 carbon atoms or alkyl with up to 6 carbon atoms,
- (B) is substituted by a 3- to 14-membered heterocyclic ring which can be saturated or unsaturated and contains 1 to 4 heteroatoms from the series N, O, S, SO, SO 2 and optionally by
- R h and R 1 may be the same or different and denote hydrogen, straight-chain, branched or cyclic alkyl or acyl having up to 6 carbon atoms
- R h and R together with the nitrogen atom form a 3- to 7-membered saturated or partially unsaturated heterocycle which optionally additionally contains an oxygen or sulfur atom or a radical of the formula -NR J ,
- R j represents hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms
- (C) is substituted by straight-chain or branched alkyl having up to 6 carbon atoms, which is imperative by one or more of the following groups
- O, S, SO, SO 2 which is optionally substituted by halogen, alkyl having up to 6 carbon atoms or alkoxy having up to 6 carbon atoms;
- R k and R 1 can be hydrogen and the other or both independently of one another are straight-chain or branched acyl having up to 10 carbon atoms, cyclic alkyl having 3 to 14 carbon atoms or R k and R 1 together form a 3- to 7-membered saturated or partially unsaturated heterocycle with the nitrogen atom, which optionally additionally contains an oxygen or sulfur atom or a radical of the formula -NR m ,
- R m is hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms, is substituted
- (D) is substituted by alkoxy with up to 6 carbon atoms, which in turn is substituted,
- R p represents hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms
- R q and R r straight-chain or branched alkyl having 1 to 10 carbon atoms, cyclic alkyl having 3 to 14 carbon atoms, Aryl with 6 to 10 carbon atoms, which is optionally substituted by halogen, alkyl with 1 to 6 carbon atoms or alkoxy with 1 to 6 carbon atoms, or 5- to 6-membered hetaryl with 1 to 3 heteroatoms from the series N, O, S, SO, SO 2 , which if necessary by
- Halogen, straight-chain or branched alkyl having 1 to 4 carbon atoms or alkoxy having 1 to 4 carbon atoms is substituted
- R s and R * may be the same or different and denote hydrogen, straight-chain or branched alkyl having 1 to 14 carbon atoms or cycloalkyl having 3 to 14 carbon atoms,
- alkyl or cycloalkyl radicals optionally being cycloalkyl having 3 to 6 carbon atoms, hydroxy, Amino, straight-chain or branched alkoxy, acyl or alkoxycarbonyl each having up to 6 carbon atoms,
- Halogen straight-chain or branched alkyl having 1 to 6 carbon atoms, cycloalkyl having 3 to 14 carbon atoms, alkoxy having 1 to 6 carbon atoms,
- R s and R * are aryl having 6 to 10 carbon atoms, which may be halogen, straight-chain or branched
- Alkyl with 1 to 6 carbon atoms, cycloalkyl with 3 to 14 carbon atoms, alkoxy with 1 to 6 carbon atoms is substituted, and / or
- R s and R 1 3- to 10-membered saturated, partially unsaturated or completely unsaturated heterocyclyl with 1 to 5 heteroatoms from the series N, O, S; SO, SO 2 , which may be halogen, straight-chain or branched alkyl having 1 to 6 carbon atoms, cycloalkyl having 3 to 14 carbon atoms. atoms, alkoxy is substituted with 1 to 6 carbon atoms,
- R s and R together with the nitrogen atom form a 3- to 7-membered saturated or partially unsaturated heterocycle which optionally additionally contains an oxygen or sulfur atom or a radical of the formula -NR U ,
- R u is hydrogen or a straight-chain or branched alkyl having up to 4 carbon atoms
- R v and R w can be the same or different and straight-chain or branched acyl with 7 to 14 carbon atoms, cyclic acyl with 3 to 6 carbon atoms, -SO 2 alkyl with 1 to 4 carbon atoms, hydroxymethyl, hydroxyethyl,
- R x and RY are identical or different and are hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms,
- R z denotes straight-chain or branched alkyl having up to 6 carbon atoms or cycloalkyl having 3 to 8 carbon atoms
- radicals R v and R w can optionally be hydrogen
- R and R ' represent the same or different straight-chain, branched or cyclic alkyl having up to 8 carbon atoms or aryl having 6 to 10 carbon atoms or benzyl,
- R 2 and R 3 including the double bond, form a phenyl ring which may be up to 3 times identical or different through formyl,
- A represents phenyl or a 5- to 6-membered aromatic or saturated heterocycle with up to 3 heteroatoms from the series S, N and / or O, which is optionally up to 3 times identical or different by mercaptyl, Hydroxy, formyl, carboxyl, straight-chain or branched acyl, alkylthio, alkyloxyacyl, alkoxy or alkoxycarbonyl each having up to 6 carbon atoms, nitro, cyano, trifluoromethyl, azido, halogen, phenyl or straight-chain or branched alkyl having up to 6 carbon atoms, which is substituted can in turn be substituted by hydroxyl, carboxyl, straight-chain or branched acyl, alkoxy or alkoxycarbonyl each having up to 5 carbon atoms,
- d represents a number 0 or 1
- R 15 and R 16 are identical or different and denote hydrogen, phenyl, benzyl or straight-chain or branched alkyl or acyl, each having up to 5 carbon atoms,
- inventive compounds of the general formula (I) can also be present in the form of their salts.
- salts with organic or inorganic bases or acids may be mentioned here.
- Physiologically acceptable salts are preferred in the context of the present invention.
- Physiologically acceptable salts of the compounds according to the invention can be salts of the substances according to the invention with mineral acids, carboxylic acids or sulfonic acids. Particularly preferred are, for example, salts with hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, ⁇ aphthalenedisulfonic acid, acetic acid. acid, propionic acid, lactic acid, tartaric acid, citric acid, fumaric acid, maleic acid or benzoic acid.
- Physiologically acceptable salts can also be metal or ammonium salts of the compounds according to the invention which have a free carboxyl group.
- metal or ammonium salts of the compounds according to the invention which have a free carboxyl group.
- Sodium, potassium, magnesium or calcium salts and ammonium salts derived from ammonia, or organic amines such as ethylamine, di- or triethylamine, di- or triethanolamine, dicyclohexylamine, dimethylaminoethanol, arginine, lysine or ethylenediamine.
- the compounds according to the invention can exist in stereoisomeric forms which either behave like image and mirror image (enantiomers) or do not behave like image and mirror image (diastereomers).
- the invention relates both to the enantiomers or diastereomers and to their respective mixtures. Like the diastereomers, the racemic forms can be separated into the stereoisomerically uniform constituents in a known manner.
- alkyl having up to 20 carbon atoms generally represents a straight-chain or branched hydrocarbon radical having 1 to 20 carbon atoms.
- Examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, isopentyl, hexyl, isohexyl, heptyl, isoheptyl, octyl and isooctyl, nonyl, decyl, dodeyl, eicosyl.
- alkenyl having up to 20 carbon atoms generally represents a straight-chain or branched hydrocarbon radical having 2 to 20 carbon atoms and one or more, preferably one or two, double bonds.
- alkenyl having up to 20 carbon atoms generally represents a straight-chain or branched hydrocarbon radical having 2 to 20 carbon atoms and one or more, preferably one or two, double bonds.
- alkynyl generally represents a straight-chain or branched hydrocarbon radical with 2 to
- Examples include ethynyl, 2-butynyl, 2-pentynyl and 2-hexynyl.
- acyl with up to 10 carbon atoms generally represents straight-chain or branched lower alkyl having 1 to 9 carbon atoms which are bonded via a carbonyl group.
- Examples include: acetyl, ethylcarbonyl, propylcarbonyl, isopropylcarbonyl, butylcarbonyl and isobutylcarbonyl.
- alkoxy generally represents a straight-chain or branched hydrocarbon radical having 1 to 14 carbon atoms which is bonded via an oxygen atom.
- alkoxy generally represents a straight-chain or branched hydrocarbon radical having 1 to 14 carbon atoms which is bonded via an oxygen atom. Examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, pentoxy, isopentoxy, hexoxy, isohexoxy, heptoxy, isoheptoxy, octoxy or isooctoxy.
- Alkoxycarbonyl can, for example, by the formula
- Alkyl stands for a straight-chain or branched hydrocarbon radical with 1 to 13 carbon atoms.
- alkoxy carbo- called onyl radicals methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl or isobutoxycarbonyl.
- Cycloalkyl generally represents a cyclic hydrocarbon radical having 3 to 8 carbon atoms. Cyclopropyl, cyclopentyl and cyclohexyl are preferred.
- Examples include cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
- Aryl generally represents an aromatic radical having 6 to 10 carbon atoms.
- Preferred aryl radicals are phenyl and naphthyl.
- Halogen in the context of the invention represents fluorine, chlorine, bromine and iodine.
- Aromatic, saturated and unsaturated heterocycles in the context of the invention generally represent a 3- to 10-membered or 5- to 6-membered heterocycle which has up to 4
- heteroatoms from the series S, N and / or O Contain heteroatoms from the series S, N and / or O and which can optionally also be bonded via a nitrogen atom.
- examples include: pyridyl, thienyl, furyl, pyrrolyl, pyrrolidinyl, piperazinyl, pyrimidyl, thiazolyl, oxazolyl, imidazolyl, tetrazolyl, morpholinyl or piperidyl.
- Hetaryl stands for an aromatic heterocyclic radical.
- Cycloalkoxy in the context of the invention is an alkoxy radical whose hydrocarbon radical is a cycloalkyl radical.
- the cycloalkyl radical generally has up to 8 carbon atoms. Examples include: cyclopropyloxy and cyclohexyloxy.
- the terms "cycloalkoxy” and “cycloalkyloxy” are used synonymously.
- Preferred compounds of the general formula (I) according to the invention are those in which
- R 1 for a radical of the formula stands,
- R 4 and R 5 are identical or different and denote hydrogen or straight-chain or branched acyl having up to 4 carbon atoms or straight-chain or branched alkyl having up to 4 carbon atoms, which may be by hydroxyl, amino or by straight-chain or branched alkoxy having up to 3 carbon atoms is substituted, or
- R 4 and R 5 together with the nitrogen atom represent a morpholine ring or a radical of the formulas
- R 7 denotes straight-chain or branched acyl having up to 4 carbon atoms
- b and b ' are the same or different and represent a number 0, 1, 2 or 3,
- a represents a number 1, 2 or 3
- R 11 denotes hydrogen or straight-chain or branched alkyl having up to 3 carbon atoms
- alkyl, alkenyl, alkynyl and cycloalkyloxy radicals are optionally substituted and the phenyl radical is necessarily substituted by carboxyl, hydroxyl, mercaptyl, nitro, cyano,
- R a and R b are the same or different and are hydrogen or straight-chain or branched acyl with up to 6 carbon atoms, cyclic acyl with 3 to 6 carbon atoms, straight means chain or branched alkyl having up to 6 carbon atoms or cycloalkyl having 3 to 8 carbon atoms, these being optionally by
- R and R b together with the nitrogen atom form a 3- to 7-membered saturated heterocycle
- R c is hydrogen or straight-chain or branched alkyl having up to 3 carbon atoms.
- R d means straight-chain or branched acyl with up to 4 carbon atoms, and or
- (B) are substituted by a 3- to 8-membered heterocyclic ring which can be saturated or unsaturated and contain 1 to 4 heteroatoms from the series N, O, S and optionally by
- R h and R may be the same or different and denote hydrogen, straight-chain, branched or cyclic alkyl or acyl having up to 4 carbon atoms
- R h and R together with the nitrogen atom form a 3- to 7-membered saturated heterocycle which optionally additionally contains an oxygen or sulfur atom or a radical of the formula
- R J represents hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms
- Carbon atoms or alkoxy is substituted with 1 to 6 carbon atoms
- R k and R 1 can be hydrogen and the other or both independently represent straight-chain or branched acyl having up to 6 carbon atoms, cyclic alkyl having 3 to 8 carbon atoms or R k and R 1 together form a 3- to 7-membered saturated heterocycle with the nitrogen atom, which optionally additionally contains an oxygen or sulfur atom or a radical of the formula -NR m ,
- R m denotes hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms
- (D) are substituted by alkoxy with up to 6 carbon atoms, which in turn is substituted by
- R n and R ° may be the same or different hydrogen or straight-chain, branched or cyclic alkyl or acyl each having up to 5 carbon atoms, or R n and R ° together with the nitrogen atom are a 3- to 7th form a membered saturated heterocycle which optionally additionally contains an oxygen or sulfur atom or a radical of the formula -NR P ,
- R p is hydrogen or straight-chain or branched alkyl having up to 3 carbon atoms
- R q and R r straight-chain or branched alkyl having 1 to 6 carbon atoms, cyclic alkyl having 3 to 8 carbon atoms,
- Aryl having 6 to 10 carbon atoms which may be by
- R s and R l may be the same or different and are hydrogen, straight-chain or branched alkyl having 1 to 10 carbon atoms. atoms or cycloalkyl having 3 to 8 carbon atoms,
- alkyl or cycloalkyl radicals optionally being cycloalkyl having 3 to 6 carbon atoms, hydroxy,
- Aryl with 6 to 10 carbon atoms which may be fluorine, chlorine, bromine, straight-chain or branched
- s and R 1 are aryl having 6 to 10 carbon atoms, which is optionally substituted by fluorine, chlorine, bromine, straight-chain or branched alkyl having 1 to 6 carbon atoms, cycloalkyl having 3 to 8 carbon atoms, alkoxy having 1 to 6 carbon atoms,
- R s and R * are 3- to 8-membered saturated heterocyclyl having 1 to 3 heteroatoms from the series N, O, S; which is optionally substituted by fluorine, chlorine, bromine, straight-chain or branched alkyl having 1 to 6 carbon atoms, cycloalkyl having 3 to 8 carbon atoms, alkoxy having 1 to 6 carbon atoms,
- R s and R ' together with the nitrogen atom form a 3- to 7-membered saturated heterocycle which optionally additionally contains an oxygen or sulfur atom or a radical of the formula -NR U ,
- R u is hydrogen or a straight-chain or branched alkyl having up to 4 carbon atoms
- R v and R w can be the same or different and straight-chain or branched acyl with 7 to 10 carbon atoms, cyclic acyl with 3 to 6 carbon atoms, -SO 2 alkyl with 1 to 4 carbon atoms, hydroxymethyl, hydroxyethyl, alkoxycarbonyl with up to 5 carbon atoms , Alkoxyalkyl with a total of up to 8 carbon atoms, acyloxymethyl with up to 6 carbon atoms in the acyl radical (preferably pivaloyloxymethyl) or the following radicals
- R x and Ry are the same or different and are hydrogen or straight-chain or branched alkyl having up to 3 carbon atoms m represents a number 0, 1 or 2 and
- R z denotes straight-chain or branched alkyl having up to 4 carbon atoms, cyclopropyl, cyclopentyl or cyclohexyl,
- radicals R v and R w can optionally be hydrogen
- R and R ' are the same or different straight-chain, branched or cyclic alkyl having up to 6 carbon atoms or aryl
- R 2 and R 3 including the double bond, form a phenyl ring which may be up to 3 times the same or different by formyl, carboxyl, hydroxy, amino, straight-chain or branched acyl, alkoxy, or
- Alkoxycarbonyl each with up to 5 carbon atoms, nitro, cyano, azido, fluorine, chlorine, bromine, phenyl or straight-chain or branched alkyl with up to 5 carbon atoms, which in turn are substituted by hydroxy, amino, carboxyl, straight-chain or branched acyl, alkoxy or Alkoxycarbonyl can each be substituted with up to 4 carbon atoms,
- Pyrimidyl, piperazinyl or pyridyl which is optionally up to 2 times identical or different by hydroxy, formyl, carboxyl, straight-chain or branched acyl, alkylthio, alkyloxyacyl, alkoxy or alkoxycarbonyl in each case up to 4 carbon atoms, fluorine, chlorine, bromine, nitro, cyano, trifluoromethyl or straight-chain or branched alkyl having up to 4 carbon atoms, which in turn is substituted by hydroxy, carboxyl, straight-chain or branched acyl, alkoxy or alkoxycarbonyl, each with up to 4 Carbon atoms can be substituted
- a number means 0 or 1
- R ' 5 and R 16 are the same or different and are hydrogen, phenyl, benzyl or straight-chain or branched alkyl or acyl each having up to 4 carbon atoms,
- R 1 for a radical of the formula
- R 1 optionally up to 2 times the same or different by hydrogen, formyl, straight-chain or branched acyl, alkoxy or alkoxycarbonyl in each case up to 4 carbon atoms, methylamino, amino, fluorine, chlorine, bromine, cyano, azido or straight-chain or branched alkyl having up to 4 carbon atoms which are in turn substituted by hydroxy, carboxyl, amino, straight-chain or branched acyl, alkoxy, alkoxycarbonyl, Acylamino can each be substituted with up to 3 carbon atoms,
- alkenyl or alkynyl have their double or triple bond at the point of attachment to the heterocycle R 1 ,
- R a and R b are identical or different and are hydrogen or straight-chain or branched acyl having up to 4 carbon atoms, cyclic acyl having 3 to 6 carbon atoms, straight-chain or branched alkyl having up to 4 carbon atoms or cycloalkyl having 3 to 6 carbon atoms, where appropriate by
- R d straight-chain or branched acyl with up to 3 carbon atoms
- (B) are substituted by a 5- to 6-membered heterocyclic ring, which can be saturated or unsaturated and contains 1 to 4 heteroatoms from the series N, O, S and optionally by
- R h and R may be the same or different and denote hydrogen, straight-chain, branched or cyclic alkyl or acyl having up to 3 carbon atoms
- R h and R together with the nitrogen atom represent a radical of the formula
- (C) are substituted by straight-chain or branched alkyl having up to 6 carbon atoms, which is imperative by one or more of the following groups
- Cyano cyclic acyl with 3 to 6 carbon atoms, alkylthio with up to 6 carbon atoms, cyclic alkyl with 3 to 14 carbon atoms, phenyl, which may be by Fluorine, chlorine, alkyl with up to 4 carbon atoms or
- Alkoxy is substituted with up to 4 carbon atoms
- O, S which is optionally substituted by fluorine, chlorine, alkyl having 1 to 4 carbon atoms or alkoxy having 1 to 4 carbon atoms,
- R k and R 1 can be hydrogen and the other or both independently represent straight-chain or branched acyl having up to 4 carbon atoms, cyclic alkyl having 3 to 6 carbon atoms or R k and R 1 together with the nitrogen atom a heterocycle of the formula
- (D) are substituted by alkoxy with up to 4 carbon atoms, which in turn is substituted by
- R n and R ° may be the same or different hydrogen or straight-chain, branched or cyclic alkyl or acyl each having up to 4 carbon atoms or R n and R ° together with the nitrogen atom form a heterocycle of the formula -N
- Phenyl radical is optionally substituted by fluorine, chlorine, alkyl, alkoxy each having 1 to 4 carbon atoms; Heteroarylthio with 5- to 6-membered hetaryl with 1 to 3 heteroatoms from the series N, O, S, which is optionally substituted by fluorine, chlorine, straight-chain or branched alkyl or alkoxy having 1 to 4 carbon atoms; are substituted,
- R q and R r straight-chain or branched alkyl having 1 to 3 carbon atoms, cyclic alkyl having 3 to 6 carbon atoms,
- Phenyl which is optionally substituted by fluorine, chlorine, alkyl having 1 to 4 carbon atoms or alkoxy having 1 to 3 carbon atoms, or 5- to 6-membered hetaryl with 1 to 3 heteroatoms from the series N, O, S, which is optionally substituted by
- R s and R ' may be the same or different and denote hydrogen, straight-chain or branched alkyl having 1 to 6 carbon atoms or cycloalkyl having 3 to 6 carbon atoms,
- alkyl or cycloalkyl radicals optionally being cycloalkyl having 3 to 6 carbon atoms, hydroxyl, amino, straight-chain or branched alkoxy, acyl or
- Alkoxycarbonyl each with up to 4 carbon atoms, Phenyl which is optionally substituted by fluorine, chlorine, straight-chain or branched alkyl having 1 to 4 carbon atoms, cycloalkyl having 3 to 6 carbon atoms, alkoxy having 1 to 4 carbon atoms;
- N, O, S which may be fluorine, chlorine, straight-chain or branched alkyl having 1 to 4 carbon atoms, cycloalkyl having 3 to 6 carbon atoms,
- Alkoxy is substituted with 1 to 4 carbon atoms
- R s and R * are phenyl which is optionally substituted by fluorine, chlorine, straight-chain or branched alkyl having 1 to 4 carbon atoms, cycloalkyl having 3 to 6 carbon atoms, alkoxy having 1 to 4 carbon atoms,
- R s and R * are 3- to 6-membered saturated heterocyclyl having 1 to 3 heteroatoms from the series N, O, S; which is optionally substituted by fluorine, chlorine, straight-chain or branched alkyl having 1 to 4 carbon atoms, cycloalkyl having 3 to 6 carbon atoms, alkoxy having 1 to 4 carbon atoms,
- R v and R w can be the same or different and hydroxymethyl
- R x and Ry can be the same or different and represent hydrogen or straight-chain or branched alkyl having 1 to 4 carbon atoms,
- R z for straight-chain or branched alkyl having up to 4 carbon atoms, cyclopropyl, cyclopentyl, cyclohexyl or aryl and m represents a number 0, 1 or 2 and
- radicals R v and R w can optionally be hydrogen
- R and R ' are the same or different straight-chain, branched or cyclic alkyl having up to 4 carbon atoms or phenyl or benzyl,
- R 2 and R 3 including the double bond, form a phenyl ring which may be identical or different up to 2 times through formyl, carboxyl, hydroxy, amino, straight-chain or branched acyl, alkoxy, or alkoxycarbonyl, each having up to 4 carbon atoms, Nitro, cyano, fluorine, chlorine,
- Phenyl or straight-chain or branched alkyl having up to 3 carbon atoms are substituted, which in turn can be substituted by hydroxy, amino, carboxyl, straight-chain or branched acyl, alkoxy or alkoxycarbonyl each having up to 3 carbon atoms,
- A represents phenyl or tetrahydropyranyl, tetrahydrofuryl, furyl or pyridyl, which may optionally be up to 2 times identical or different by formyl, carboxyl, straight-chain or branched acyl, alkylthio, alkyloxyacyl, alkoxy or alkoxycarbonyl each having up to 3 carbon atoms, fluorine, Chlorine, bromine, nitro, cyano, trifluoromethyl or straight-chain or branched alkyl having up to 3 carbon atoms are substituted, that can in turn be substituted by hydroxyl, carboxyl, straight-chain or branched acyl, alkoxy or alkoxycarbonyl each having up to 3 carbon atoms,
- d represents a number 0 or 1
- R 15 and R 16 are identical or different and are hydrogen or straight-chain or branched alkyl or acyl each having up to 3 carbon atoms,
- R 1 for a radical of the formula
- pyrimidyl radical listed above may be up to 2 times identical or different by methyl, ethyl, isopropyl, fluorine, amino, cyano, methoxy, chlorine, hydroxymethyl or by a radical of the formula
- A represents phenyl, which is optionally substituted by fluorine or cyano
- D represents triflate or halogen, preferably chlorine or bromine
- L represents a radical of the formula -SnR 1 TTR 19 , ZnR 2U , iodine or triflate
- R 17 , R 18 and R 19 are identical or different and represent straight-chain or branched alkyl having up to 4 carbon atoms,
- R 20 represents halogen
- R 1 has the meaning given above
- T represents triflate or halogen, preferably chlorine or bromine
- T represents a radical of the formula SnR 17 R 18 R 19 , ZnR 20 or BR 2, R 22 , wo ⁇ n
- R 17 ' , R 18' , R ' 9' and R 20 ' have the abovementioned meaning of R 17 , R 18 , R 19 and R 20 and are the same or different with this,
- R 21 and R 22 are the same or different and are hydroxy, aryloxy having 6 to 10 carbon atoms or straight-chain or branched
- alkyl or alkoxy each having up to 5 carbon atoms, or together form a 5- or 6-membered carbocyclic ring,
- R 2 and R 3 have the meaning given above
- R r represents one of the above-mentioned substituents of the 6-membered aromatic heterocycle R 1
- R 1 , R 2 , R 3 and / or A are varied or introduced by customary methods, preferably by reduction, oxidation, removal of protective groups and / or by nucleophilic substitution.
- Inert organic solvents which do not change under the reaction conditions are suitable as solvents for the individual steps of processes [A], [B] and [C].
- ethers such as diethyl ether or tetrahydrofuran, DME, dioxane, alcohols such as methanol and ethanol, halogenated hydrocarbons such as dichloromethane, trichloromethane, tetrachloromethane, 1,2-dichloroethane, trichloroethane, tetrachloroethane, 1,2-dichloroethane or trichlorethylene, hydrocarbons such as benzene, xylene, toluene, hexane, cyclohexane, or petroleum fractions, nitromethane, dimethylformamide, acetone, acetonitrile or hexamethylphosphoric triamide. It is also possible to mix the
- Tetrahydrofuran, dimethylformamide, toluene, dioxane or dimethoxyethane is particularly preferred.
- inorganic or organic bases can be used as bases for the processes according to the invention.
- bases preferably include alkali metal hydroxides such as sodium hydroxide or potassium hydroxide, alkaline earth metal hydroxides such as barium hydroxide, alkali metal carbonates such as sodium carbonate or potassium carbonate, alkaline earth metal carbonates such as calcium carbonate, or alkali metal or alkaline earth metal alcoholates such as sodium or potassium methoxide, sodium or potassium ethanolate or potassium tert .butylate, or organic amines (trialkyl (C r C 6 ) amines) such as triethylamine, or heterocycles such as 1,4-diazabicyclo [2.2.2] octane (DABCO), 1,8-diazabicyclo [5.4.
- alkali metal hydroxides such as sodium hydroxide or potassium hydroxide
- alkaline earth metal hydroxides such as barium hydroxide
- alkali metal carbonates such as sodium carbonate or potassium
- DBU undec-7-ene
- pyridine diaminopyridine
- methylpiperidine methylpiperidine
- morpholine alkali metals such as sodium and their hydrides such as sodium hydride as bases.
- sodium and potassium carbonate, triethylamine and sodium hydride are preferred.
- the base is used in an amount of 1 mol to 5 mol, preferably 1 mol to 3 mol, based on 1 mol of the compound of the general formula (II).
- the reaction is generally carried out in a temperature range from 0 ° C. to 150 ° C., preferably from + 20 ° C. to + 110 ° C.
- the reaction can be carried out under normal, elevated or reduced pressure (for example 0.5 to 5 bar). Generally one works at normal pressure.
- Protonic acids are generally suitable as acids for the cyclization. These preferably include inorganic acids such as hydrochloric acid or sulfuric acid, or organic carboxylic acids with 1-6 C atoms, optionally substituted by fluorine, chlorine and / or bromine, such as acetic acid, trifluoroacetic acid, trichloroacetic acid or propionic acid, or sulfonic acids with -C ⁇ alkyl radicals or aryl residues such as methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid or toluenesulfonic acid.
- inorganic acids such as hydrochloric acid or sulfuric acid, or organic carboxylic acids with 1-6 C atoms, optionally substituted by fluorine, chlorine and / or bromine, such as acetic acid, trifluoroacetic acid, trichloroacetic acid or propionic acid, or sulfonic acids with -C ⁇ alky
- the catalytic hydrogenation can generally be carried out using hydrogen in water or in inert organic solvents such as alcohols, ethers or halogenated hydrocarbons, or mixtures thereof, with catalysts such as Raney nickel, palladium,
- the chlorination is generally carried out using the customary chlorinating agents, for example PC1 3 , PC1 5 , POCl 3 or elemental chlorine. Is preferred within the customary chlorinating agents, for example PC1 3 , PC1 5 , POCl 3 or elemental chlorine. Is preferred within the customary chlorinating agents, for example PC1 3 , PC1 5 , POCl 3 or elemental chlorine. Is preferred within the customary chlorinating agents, for example PC1 3 , PC1 5 , POCl 3 or elemental chlorine. Is preferred within the customary chlorinating agents, for example PC1 3 , PC1 5 , POCl 3 or elemental chlorine. Is preferred within the customary chlorinating agents, for example PC1 3 , PC1 5 , POCl 3 or elemental chlorine. Is preferred within the customary chlorinating agents, for example PC1 3 , PC1 5 , POCl 3 or elemental chlorine. Is preferred within the customary chlorinating agents, for example PC1 3
- the reductions are generally carried out using reducing agents, preferably those which are suitable for the reduction of carbonyl to hydroxy compounds.
- the reduction is preferably carried out using complex metal hydrides such as, for example, lithium boranate, sodium boranate, potassium boranate, zinc boranate, lithium trialkylhydridoboranate, diisobutylaluminium hydride or lithium aluminum hydride.
- the reduction is very particularly preferably carried out using diisobutylaluminum hydride and sodium borohydride.
- the reducing agent is generally used in an amount of 1 mol to 6 mol, preferably 1 mol to 4 mol, based on 1 mol of the compounds to be reduced.
- the reduction generally takes place in a temperature range from -78 ° C. to + 50 ° C., preferably from -78 ° C. to 0 ° C. in the case of the DIBAH, from 0 ° C. to room temperature in the case of the NaBH 4
- the reduction generally proceeds at normal pressure, but it is also possible to work at elevated or reduced pressure.
- solvents for process [B] are: ethers, such as diethyl ether or tetrahydrofuran, DME, dioxane, halogenated hydrocarbons such as dichloromethane, trichloromethane, tetrachloromethane, 1,2-dichloroethane, trichloroethane, tetrachloroethane, 1, 2-dichloroethylene or trichlorethylene, hydrocarbons such as benzene, xylene, toluene, hexane, cyclohexane, or petroleum fractions, nitromethane, dimethylformamide, acetone, acetonitrile or hexamethylphosphoric triamide. It is also possible Use mixtures of solvents. Tetrahydrofuran, dimethylformamide, toluene, dioxane or dimethoxyethane are particularly preferred.
- the reaction is generally carried out in a temperature range from 0 ° C. to 150 ° C., preferably from 110 ° C. to 150 ° C.
- the reaction can be carried out at normal, elevated or reduced pressure (e.g. 0.5 to 5 bar). Generally one works at normal pressure.
- PdCl 2 (P (C 6 H 5 ) 3 ) 2 palladium-bis-dibenzylidene acetone (Pd (dba) 2 ), [l, l'-bis (diphenylphosphino) ferrocene are generally suitable as palladium compounds in the context of the present invention ] -Palladium (II) chloride (Pd (dppf) Cl 2 ) or Pd (P (C 6 H 5 ) 3 ) 4 .
- Pd (P (C 6 H 5 ) 3 ) 4 is preferred.
- Process [C] takes place in a temperature range from 55 ° C to 120 ° C, preferably at 80 ° C.
- either the free amidine base is used.
- the enamines act as solvents.
- the amidines are reacted in the form of their salts, preferably hydrochlorides, in the presence of a base, preferably sodium methoxide or potassium tert-butoxide in alcohols, preferably methanol or tert-butanol.
- the use of the enols is reacted with the free amidine base in an inert solvent, preferably toluene.
- the process [C] can be carried out at normal, elevated or reduced pressure (for example 0.5 to 5 bar). Generally one works at normal pressure.
- the amidines of the general formula (VI) are new and therefore a further subject of the invention. They can be prepared by using the compounds of the general formula (VIII)
- R 2 and R 3 have the meaning given above
- R 2 and R 3 have the meaning given above
- bases preferably sodium carbonate.
- the conversion of the nitrile into the imino ether can be carried out in acid, e.g. with HCl / alcohol mixtures as in basic such as e.g. with methanol sodium methanolate.
- the pyrimidine is prepared by customary methods.
- the imino ether can also first be converted into an amidine using ammonia or its salts, and this can be reacted with enamines either as a free base or as a salt.
- aldehyde equivalents such as e.g. Acetals, aminals, enol ethers, aldehydes or enols can be used.
- the enamines can e.g. from C-H-acidic compounds such as acetonitrile derivatives by known methods by reaction with dimethylformamide derivatives such as e.g. Bis (dimethylamino) tert-butoxymethane, dialkoxy-dialkylamino-methanes can be produced.
- C-H-acidic compounds such as acetonitrile derivatives
- dimethylformamide derivatives such as e.g. Bis (dimethylamino) tert-butoxymethane, dialkoxy-dialkylamino-methanes
- Alcohols such as methanol or ethanol are suitable as solvents for the reaction of the compounds of the general formulas (IX) -> (X). Methanol is preferred.
- the reaction takes place in a temperature range from 0 ° C to 40 ° C, preferably at room temperature.
- the reaction can be carried out at normal, elevated or reduced pressure (for example 0.5 to 5 bar). Generally one works at normal pressure.
- Inorganic or organic bases are suitable as bases for the release of the free amidine bases from the hydrochlorides (X).
- X hydrochlorides
- alkali metal hydroxides such as sodium hydroxide or potassium hydroxide
- alkaline earth metal hydroxides such as barium hydroxide
- alkali metal carbonates such as sodium carbonate or potassium carbonate
- alkaline earth metal carbonates such as calcium carbonate
- alkali alcoholates such as potassium tert-butoxide.
- Sodium carbonate and potassium tert-butoxide are preferred.
- the reaction takes place in a temperature range from 0 ° C to 40 ° C, preferably at room temperature.
- the reaction can be carried out at normal, elevated or reduced pressure (e.g. 0.5 to 5 bar). Generally one works at normal pressure.
- the compounds of the formula (VIII) can be prepared by reacting the corresponding 3-cyanoindazoles with compounds of the general formula (XIII)
- inert solvents preferably with tetrahydrofuran in the presence of a base, preferably sodium hydride.
- the compounds of the general formula (I) according to the invention lead to vascular relaxation, platelet aggregation inhibition and to a reduction in blood pressure as well as an increase in coronary blood flow. These effects are mediated by direct stimulation of soluble guanylate cyclase and an intracellular increase in cGMP.
- the compounds of the general formula (I) according to the invention enhance the action of substances which increase the cGMP level, such as EDRF (endothelium derived relaxing factor), NO donors, protoporphyrin IX, arachidonic acid or phenylhydrazine derivatives.
- cardiovascular diseases such as, for example, for the treatment of high blood pressure and cardiac insufficiency, stable and unstable angina pectoris, peripheral and cardiac vascular diseases, of arrhythmias, for the treatment of thromboembolic disorders and ischemia such as myocardial infarction, stroke, transistoric and Ischemic attacks, peripheral circulatory disorders, prevention of restenoses such as after thrombolysis therapies, percutaneous transluminal angioplasties (PTA), percutaneously transluminal coronary angioplasties (PTCA), bypass and for the treatment of arteriosclerosis and diseases of the genitourinary system such as prostate erectile dysfunction, female prostate hypertrophy Dysfunction and incontinence are used.
- PTA percutaneous transluminal angioplasties
- PTCA percutaneously transluminal coronary angioplasties
- the invention comprises the combination of the invention
- Organic nitrates and NO donors in the context of the invention are generally substances which are therapeutic via the release of NO or NO species
- the invention also includes combination with compounds that inhibit the degradation of cyclic guanosine monophosphate (cGMP). These are in particular
- Collagenase solution isolated.
- the cells were then cultured in culture medium at 37 ° C./5% CO 2 until confluence was reached.
- the cells were passaged, sown in 24-well cell culture plates and subcultivated until they reached confluence ( ⁇ 2 ⁇ 10 5 cells / well).
- the culture medium was aspirated to stimulate endothelial guanylate cyclase and the cells were washed once with Ringer's solution. After removing the Ringer's solution, the cells were incubated in stimulation buffer with or without NO donor (sodium nitroprusside, SNP or DEA NO 1 ⁇ M) for 10 minutes at 37 ° C./5% CO 2 .
- NO donor sodium nitroprusside, SNP or DEA NO 1 ⁇ M
- test substances final concentration 1 ⁇ M
- buffer solution was aspirated and 4 ° C stop buffer was added to the cells.
- the cells were then lysed at -20 ° C for 16 hours.
- the supernatants containing the intracellular cGMP were then removed and the cGMP concentrations were determined by the cGMP-SPA system (Amersham Buchler, Braunschweig).
- Rabbits are anesthetized and bled by the blow of the neck.
- the aorta is removed, adherent tissue is removed, divided into 1.5 mm wide rings and individually pretensioned in 5 ml organ baths at 37 ° C, carbogen gassers
- Krebs-Henseleit solution with the following composition (mM): NaCl: 119; KC1: 4.8; CaCl 2 x 2 H 2 O: 1; MgSO 4 x 7 H 2 O; 1.4; KH 2 PO 4 : 1.2; NaHCO3: 25; Glucose: 10.
- the contraction force is recorded with Statham UC2 cells, amplified and digitized via A / D converter (DAS-1802 HC, Keithley Instruments Munich) and recorded in parallel on a line recorder. To create a contraction, phenylephrine is added cumulatively to the bath in increasing concentration.
- the substance to be examined is examined in increasing doses in each subsequent run and the level of the contraction is compared with the level of the contraction reached in the last previous run. From this the concentration is calculated which is required to reduce the level of the control value by 50% (IC 50 ).
- the standard application volume is 5 ⁇ l, the DMSO content in the bath solution corresponds to 0.1%.
- the animals were housed individually in Type III cages positioned on the individual recipient stations and were adapted to a 12 hour light / dark rhythm. Water and feed were freely available.
- the blood pressure of each rat was recorded every 5 minutes for 10 seconds.
- the measuring points were combined for a period of 15 minutes and the mean value was calculated from these values.
- test compounds were dissolved in a mixture of Transcutol (10%), Cremophor (20%), H 2 O (70%) and administered orally using a gavage in a volume of 2 ml / kg body weight.
- the test doses were between 0.3 - 30 mg / kg body weight.
- Blood from healthy volunteers of both sexes was used to determine platelet aggregation. 9 parts of blood were added to one part of 3.8% sodium citrate solution as an anticoagulant. The blood was centrifuged at 900 rpm for 20 min. The pH of the platelet-rich plasma obtained was adjusted to pH 6.5 using ACD solution (sodium citrate / citric acid / glucose). The platelets were then centrifuged off and taken up in buffer and centrifuged again. The platelet precipitate was taken up in buffer and 2 mmol / 1 CaCl 2 were additionally added.
- ACD solution sodium citrate / citric acid / glucose
- aggregation measurements For the aggregation measurements, aliquots of the platelet suspension with the test substance were incubated at 37 ° C. for 10 min. The aggregation was then triggered by adding collagen in an aggregometer and determined using the turbidometric method according to Born (Born, GN.R., J. Physiol. (London), 168, 178-195, 1963) at 37 ° C.
- Formula (I) also represents active substances for combating diseases in the central nervous system which are characterized by disorders of the ⁇ O / cGMP system. In particular, they are suitable for eliminating cognitive deficits, for improving learning and memory and for treating Alzheimer's disease. They are also suitable for the treatment of diseases of the central nervous system such as
- Anxiety tension and depression, central nervous system-related sexual dysfunctions and sleep disorders, as well as for the regulation of pathological disorders in the intake of food, stimulants and addictive substances.
- the active ingredients are also suitable for regulating cerebral blood flow and are therefore effective means of combating migraines.
- Formula (I) can be used to combat painful conditions.
- the present invention includes pharmaceutical preparations which, in addition to non-toxic, inert pharmaceutically suitable excipients, contain the compounds of the general formula (I) according to the invention and processes for the preparation of these preparations.
- the active ingredient can optionally also be in microencapsulated form in one or more of the above-mentioned carriers.
- the therapeutically active compounds of the general formula (I) should be present in the pharmaceutical preparations listed above in a concentration of about 0.1 to 99.5, preferably about 0.5 to 95% by weight of the total mixture.
- the pharmaceutical preparations listed above can also contain further active pharmaceutical ingredients.
- the active ingredient (s) according to the invention in total amounts of about 0.5 to about 500, preferably 5 to 100 mg / kg of body weight per 24 hours, optionally in the form multiple doses to achieve the desired results.
- a single dose contains the active ingredient (s) according to the invention preferably in amounts of about 1 to about 80, in particular 3 to 30 mg / kg body weight.
- Phosphonic acid ester The solution is first freed from the methanol at 40 ° C. and 20 mbar on a rotary evaporator, then at room temperature in a high vacuum.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002346698A CA2346698A1 (en) | 1998-10-09 | 1999-09-29 | Novel heterocyclyl-methyl-substituted pyrazoles |
JP2000575860A JP2002527435A (ja) | 1998-10-09 | 1999-09-29 | 新規なヘテロシクリル−メチル置換ピラゾール類 |
EP99950564A EP1119566A1 (de) | 1998-10-09 | 1999-09-29 | Neue heterocyclyl-methyl-substituierte pyrazole |
AU63300/99A AU6330099A (en) | 1998-10-09 | 1999-09-29 | Novel heterocyclyl-methyl-substituted pyrazoles |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19846514A DE19846514A1 (de) | 1998-10-09 | 1998-10-09 | Neue Heterocyclyl-methyl-substituierte Pyrazole |
DE19846514.9 | 1998-10-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000021954A1 true WO2000021954A1 (de) | 2000-04-20 |
Family
ID=7883905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1999/007202 WO2000021954A1 (de) | 1998-10-09 | 1999-09-29 | Neue heterocyclyl-methyl-substituierte pyrazole |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1119566A1 (de) |
JP (1) | JP2002527435A (de) |
AU (1) | AU6330099A (de) |
CA (1) | CA2346698A1 (de) |
DE (1) | DE19846514A1 (de) |
WO (1) | WO2000021954A1 (de) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003004503A1 (de) * | 2001-07-04 | 2003-01-16 | Bayer Healthcare Ag | Morpholin-überbrückte pyrazolopyridinderivate |
US6693102B2 (en) | 2000-11-22 | 2004-02-17 | Bayer Aktiengesellschaft | Pyridine-substituted pyrazolopyridine derivatives |
WO2004031186A1 (de) * | 2002-09-26 | 2004-04-15 | Bayer Healthcare Ag | Morpholin-überbrückte indazolderivate |
US6903089B1 (en) | 2000-11-22 | 2005-06-07 | Bayer Aktiengesellschaft | Lactam-substituted pyrazolopyridine derivatives |
US6919345B2 (en) | 2001-05-11 | 2005-07-19 | Bayer Aktiengesellschaft | Sulfonate substituted pyrazol pyridine derivatives |
JP2006502119A (ja) * | 2002-07-18 | 2006-01-19 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 新規2,5−二置換ピリミジン誘導体 |
US7105523B2 (en) | 2000-11-22 | 2006-09-12 | Bayer Aktiengeselischaft | Carbamate-substituted pyrazolopyridine-derivatives |
US7115599B2 (en) | 2000-11-22 | 2006-10-03 | Bayer Aktiengesellschaft | Sulfonamide-substituted pyrazolopyridine compounds |
US7173037B2 (en) | 2002-05-08 | 2007-02-06 | Bayer Healthcare Ag | Carbamate-substituted pyrazolopyridines |
DE102007026392A1 (de) | 2007-06-06 | 2008-12-11 | Bayer Healthcare Ag | Lösungen für die Perfusion und Konservierung von Organen und Geweben |
DE102007028320A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE102007028406A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE102007028407A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE102007028319A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
EP2138178A1 (de) | 2008-06-28 | 2009-12-30 | Bayer Schering Pharma Aktiengesellschaft | Oxazolidninone zur Behandlung der chronisch obstruktiven Lungenerkrankung (COPD) und/oder Asthma |
US7645752B2 (en) | 2006-01-13 | 2010-01-12 | Wyeth Llc | Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors |
US8293738B2 (en) | 2010-05-12 | 2012-10-23 | Abbott Laboratories | Indazole inhibitors of kinase |
WO2012165399A1 (ja) | 2011-05-30 | 2012-12-06 | アステラス製薬株式会社 | イミダゾピリジン化合物 |
WO2013167669A1 (en) | 2012-05-10 | 2013-11-14 | Bayer Pharma Aktiengesellschaft | Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof |
WO2014084312A1 (ja) | 2012-11-30 | 2014-06-05 | アステラス製薬株式会社 | イミダゾピリジン化合物 |
CN103974948A (zh) * | 2011-10-06 | 2014-08-06 | 拜耳医药股份有限公司 | 在治疗过度增殖性疾病中用作bub1激酶抑制剂的取代的苄基吲唑 |
US9241942B2 (en) | 2007-06-08 | 2016-01-26 | Mannkind Corporation | IRE-1α inhibitors |
WO2017106175A2 (en) | 2015-12-14 | 2017-06-22 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION |
US9993476B2 (en) | 2010-05-26 | 2018-06-12 | Adverio Pharma Gmbh | Substituted 5-flouro-1H-pyrazolopyridines and their use |
WO2018111795A2 (en) | 2016-12-13 | 2018-06-21 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of esophageal motility disorders |
US10350206B2 (en) | 2014-09-19 | 2019-07-16 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as BUB1 inhibitors |
WO2020014504A1 (en) | 2018-07-11 | 2020-01-16 | Cyclerion Therapeutics, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS |
WO2024131860A1 (zh) * | 2022-12-21 | 2024-06-27 | 广东东阳光药业股份有限公司 | 氟取代的吲唑化合物的晶型及其用途 |
WO2024131850A1 (zh) * | 2022-12-21 | 2024-06-27 | 广东东阳光药业股份有限公司 | 氟取代的吲唑化合物的晶型及其用途 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003076408A2 (en) * | 2002-03-08 | 2003-09-18 | Abbott Laboratories | Indazole derivatives that are activators of soluble guanylate cyclase |
DE10232571A1 (de) * | 2002-07-18 | 2004-02-05 | Bayer Ag | 4-Aminosubstituierte Pyrimidinderivate |
WO2005026128A1 (en) * | 2003-09-04 | 2005-03-24 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
DE102006043443A1 (de) | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
DE102008063992A1 (de) | 2008-12-19 | 2010-09-02 | Lerner, Zinoviy, Dipl.-Ing. | Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung |
TR201816146T4 (tr) | 2009-11-27 | 2018-11-21 | Adverio Pharma Gmbh | Meti̇l-{4,6-di̇ami̇no-2-[1-(2-florobenzi̇l)-1h-pi̇razolo[3,4-b]pi̇ri̇di̇n-3-i̇l]pi̇ri̇mi̇di̇n-5-i̇lmeti̇l}karbamatin farmasöti̇k etken madde olarak kullanima yöneli̇k olarak üreti̇lmesi̇ne yöneli̇k yöntem. |
UY33041A (es) | 2009-11-27 | 2011-06-30 | Bayer Schering Pharma Aktienegesellschaft | Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico |
ES2864009T3 (es) | 2011-11-25 | 2021-10-13 | Adverio Pharma Gmbh | 5-Fluoro-1H-pirazolopiridinas sustituidas en forma cristalina |
EA201500852A1 (ru) | 2013-02-21 | 2016-02-29 | Адверио Фарма Гмбх | Формы метил {4,6-диамино-2-[1-(2-фторбензил)-1н-пиразоло[3,4-в]пиридино-3-ил]пиримидино-5-ил}метил карбамата |
EP3609883B1 (de) * | 2017-04-11 | 2022-06-29 | Sunshine Lake Pharma Co., Ltd. | Fluorsubstituierte indazolverbindungen und verwendungen davon |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0641564A1 (de) * | 1992-05-21 | 1995-03-08 | Yoshitomi Pharmaceutical Industries, Ltd. | Optisch aktive kondensierte pyrazolverbindungen zur verwendung in der behandlung von thrombozytopenie und erythropenie |
EP0667345A1 (de) * | 1994-02-14 | 1995-08-16 | Yung Shin Pharm. Ind. Co. Ltd. | 1-Benzyl-3(substituiertes Aryl)-kondensierte Pyrazolderivate als Inhibitoren der Blutplattchenaggregation |
DE19642255A1 (de) * | 1996-10-14 | 1998-04-16 | Bayer Ag | Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten |
DE19642320A1 (de) * | 1996-10-14 | 1998-04-16 | Bayer Ag | Neue 1-Methyl-heterocyclyl-substituierte Pyrazole |
-
1998
- 1998-10-09 DE DE19846514A patent/DE19846514A1/de not_active Withdrawn
-
1999
- 1999-09-29 AU AU63300/99A patent/AU6330099A/en not_active Abandoned
- 1999-09-29 EP EP99950564A patent/EP1119566A1/de not_active Withdrawn
- 1999-09-29 WO PCT/EP1999/007202 patent/WO2000021954A1/de not_active Application Discontinuation
- 1999-09-29 CA CA002346698A patent/CA2346698A1/en not_active Abandoned
- 1999-09-29 JP JP2000575860A patent/JP2002527435A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0641564A1 (de) * | 1992-05-21 | 1995-03-08 | Yoshitomi Pharmaceutical Industries, Ltd. | Optisch aktive kondensierte pyrazolverbindungen zur verwendung in der behandlung von thrombozytopenie und erythropenie |
EP0667345A1 (de) * | 1994-02-14 | 1995-08-16 | Yung Shin Pharm. Ind. Co. Ltd. | 1-Benzyl-3(substituiertes Aryl)-kondensierte Pyrazolderivate als Inhibitoren der Blutplattchenaggregation |
DE19642255A1 (de) * | 1996-10-14 | 1998-04-16 | Bayer Ag | Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten |
DE19642320A1 (de) * | 1996-10-14 | 1998-04-16 | Bayer Ag | Neue 1-Methyl-heterocyclyl-substituierte Pyrazole |
Cited By (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7105523B2 (en) | 2000-11-22 | 2006-09-12 | Bayer Aktiengeselischaft | Carbamate-substituted pyrazolopyridine-derivatives |
US6903089B1 (en) | 2000-11-22 | 2005-06-07 | Bayer Aktiengesellschaft | Lactam-substituted pyrazolopyridine derivatives |
US7115599B2 (en) | 2000-11-22 | 2006-10-03 | Bayer Aktiengesellschaft | Sulfonamide-substituted pyrazolopyridine compounds |
US6693102B2 (en) | 2000-11-22 | 2004-02-17 | Bayer Aktiengesellschaft | Pyridine-substituted pyrazolopyridine derivatives |
US7291622B2 (en) | 2000-11-22 | 2007-11-06 | Bayer Aktiengesellschaft | Medical uses of carbamate-substituted pyrazolo-pyridine derivatives |
US7317016B2 (en) | 2001-05-11 | 2008-01-08 | Bayer Aktiengesellschaft | Methods of treating medical conditions using sulfonate-substituted pyrazolopyridine derivatives |
US6919345B2 (en) | 2001-05-11 | 2005-07-19 | Bayer Aktiengesellschaft | Sulfonate substituted pyrazol pyridine derivatives |
WO2003004503A1 (de) * | 2001-07-04 | 2003-01-16 | Bayer Healthcare Ag | Morpholin-überbrückte pyrazolopyridinderivate |
US7173037B2 (en) | 2002-05-08 | 2007-02-06 | Bayer Healthcare Ag | Carbamate-substituted pyrazolopyridines |
JP2006502119A (ja) * | 2002-07-18 | 2006-01-19 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 新規2,5−二置換ピリミジン誘導体 |
US7427617B2 (en) | 2002-09-26 | 2008-09-23 | Bayer Healthcare Ag | Morpoline-bridged indazole derivatives |
WO2004031186A1 (de) * | 2002-09-26 | 2004-04-15 | Bayer Healthcare Ag | Morpholin-überbrückte indazolderivate |
US7645752B2 (en) | 2006-01-13 | 2010-01-12 | Wyeth Llc | Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors |
DE102007026392A1 (de) | 2007-06-06 | 2008-12-11 | Bayer Healthcare Ag | Lösungen für die Perfusion und Konservierung von Organen und Geweben |
US9241942B2 (en) | 2007-06-08 | 2016-01-26 | Mannkind Corporation | IRE-1α inhibitors |
US9981901B2 (en) | 2007-06-08 | 2018-05-29 | Fosun Orinove Pharmatech, Inc. | IRE-1α inhibitors |
US9546149B2 (en) | 2007-06-08 | 2017-01-17 | Mannkind Corporation | IRE-1α inhibitors |
DE102007028320A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE102007028406A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE102007028407A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE102007028319A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
EP2138178A1 (de) | 2008-06-28 | 2009-12-30 | Bayer Schering Pharma Aktiengesellschaft | Oxazolidninone zur Behandlung der chronisch obstruktiven Lungenerkrankung (COPD) und/oder Asthma |
US8293738B2 (en) | 2010-05-12 | 2012-10-23 | Abbott Laboratories | Indazole inhibitors of kinase |
US12064429B2 (en) | 2010-05-26 | 2024-08-20 | Adverio Pharma Gmbh | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
US11439642B2 (en) | 2010-05-26 | 2022-09-13 | Adverio Pharma Gmbh | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
US10736896B2 (en) | 2010-05-26 | 2020-08-11 | Adverio Pharma Gmbh | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
US9993476B2 (en) | 2010-05-26 | 2018-06-12 | Adverio Pharma Gmbh | Substituted 5-flouro-1H-pyrazolopyridines and their use |
WO2012165399A1 (ja) | 2011-05-30 | 2012-12-06 | アステラス製薬株式会社 | イミダゾピリジン化合物 |
CN103974948A (zh) * | 2011-10-06 | 2014-08-06 | 拜耳医药股份有限公司 | 在治疗过度增殖性疾病中用作bub1激酶抑制剂的取代的苄基吲唑 |
EP2763982B1 (de) * | 2011-10-06 | 2018-01-10 | Bayer Pharma Aktiengesellschaft | Substituierte benzylindazole zur verwendung als bub1-kinasehemmer bei der behandlung hyperproliferativer erkrankungen |
US10604532B2 (en) | 2011-10-06 | 2020-03-31 | Bayer Intellectual Property Gmbh | Substituted benzylindazoles for use as BUB1 kinase inhibitors in the treatment of hyperproliferative diseases |
US10266548B2 (en) | 2011-10-06 | 2019-04-23 | Bayer Intellectual Property Gmbh | Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases |
US10221247B2 (en) | 2012-05-10 | 2019-03-05 | Bayer Pharma Aktiengesellschaft | Antibodies capable of binding to the coagulation factor XIa and uses thereof |
US10040866B2 (en) | 2012-05-10 | 2018-08-07 | Bayer Pharma Aktiengesellschaft | Nucleic acids and host cells expressing antibodies capable of binding to the coagulation factor XIa and uses thereof |
US9783614B2 (en) | 2012-05-10 | 2017-10-10 | Bayer Pharma Aktiengesellschaft | Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor Xia and uses thereof |
US11046783B2 (en) | 2012-05-10 | 2021-06-29 | Bayer Pharma Aktiengesellschaft | Antibodies capable of binding to the coagulation factor XIa and uses thereof |
WO2013167669A1 (en) | 2012-05-10 | 2013-11-14 | Bayer Pharma Aktiengesellschaft | Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof |
WO2014084312A1 (ja) | 2012-11-30 | 2014-06-05 | アステラス製薬株式会社 | イミダゾピリジン化合物 |
US10350206B2 (en) | 2014-09-19 | 2019-07-16 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as BUB1 inhibitors |
WO2017106175A2 (en) | 2015-12-14 | 2017-06-22 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION |
WO2018111795A2 (en) | 2016-12-13 | 2018-06-21 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of esophageal motility disorders |
WO2020014504A1 (en) | 2018-07-11 | 2020-01-16 | Cyclerion Therapeutics, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS |
WO2024131860A1 (zh) * | 2022-12-21 | 2024-06-27 | 广东东阳光药业股份有限公司 | 氟取代的吲唑化合物的晶型及其用途 |
WO2024131850A1 (zh) * | 2022-12-21 | 2024-06-27 | 广东东阳光药业股份有限公司 | 氟取代的吲唑化合物的晶型及其用途 |
Also Published As
Publication number | Publication date |
---|---|
DE19846514A1 (de) | 2000-04-20 |
CA2346698A1 (en) | 2000-04-20 |
JP2002527435A (ja) | 2002-08-27 |
AU6330099A (en) | 2000-05-01 |
EP1119566A1 (de) | 2001-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000021954A1 (de) | Neue heterocyclyl-methyl-substituierte pyrazole | |
EP0944631B1 (de) | Neue substituierte pyrazolderivate zur behandlung von herzkreislauferkrankungen | |
EP1102767B1 (de) | Substituierte pyrazolderivate | |
EP1102768B1 (de) | Mit sechsgliedrigen heterocyclischen ringen kondensierte substituierte pyrazolderivate | |
EP1339714B1 (de) | Neue sulfonamid-substituierte pyrazolopyridinderivate | |
EP1339716B1 (de) | lactam-substituierte pyrazolopyridinderivate | |
EP0934311B1 (de) | Neue heterocyclylmethyl-substituierte pyrazolderivate und ihre verwendung in der behandlung von herz-kreislauf-erkrankungen | |
DE10057751A1 (de) | Neue Carbamat-substituierte Pyrazolopyridinderivate | |
WO2003004503A1 (de) | Morpholin-überbrückte pyrazolopyridinderivate | |
WO2002042301A1 (de) | Neue pyridin-substituierte pyrazolopyridinderivate | |
DE19834045A1 (de) | (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin | |
WO2003086407A1 (de) | Verwendung von stimulatoren der löslichen guanylatcyclase zur behandlung von glaukom | |
EP1525203A1 (de) | 4-aminosubstituierte pyrimidinderivate | |
DE10021069A1 (de) | Substituiertes Pyrazolderivat | |
DE10244810A1 (de) | Neue Morpholin-überbrückte Indazolderivate | |
EP0473550A1 (de) | Indolonaphthyridine | |
WO1990007503A1 (de) | Substituierte 3-azabicyclo[3.1.1]heptane, ihre herstellung und ihre verwendung | |
DE10122895A1 (de) | Neue Lactam-substituierte Pyrazolopyridinderivate | |
DD296925A5 (de) | Verfahren zur herstellung von substituierten 1,4-dihydro-4-oxonaphthyridin-3-carboxylat-verbindungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 1999 63300 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999950564 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2346698 Country of ref document: CA Ref country code: CA Ref document number: 2346698 Kind code of ref document: A Format of ref document f/p: F Ref country code: JP Ref document number: 2000 575860 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1999950564 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09807231 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999950564 Country of ref document: EP |